



FINANCIAL STATEMENTS

DECEMBER 31, 2016 AND 2015

	PAGE NO.
INDEPENDENT AUDITOR'S REPORT	1
STATEMENTS OF FINANCIAL POSITION DECEMBER 31, 2016 AND 2015	2
STATEMENTS OF ACTIVITIES Years ended DECEMBER 31, 2016 AND 2015	3 and 4
STATEMENTS OF FUNCTIONAL EXPENSES Years ended DECEMBER 31, 2016 AND 2015	5 and 6
STATEMENTS OF CASH FLOWS Years ended DECEMBER 31, 2016 AND 2015	7
NOTES TO THE FINANCIAL STATEMENTS	8 through 12



INDEPENDENT AUDITOR'S REPORT

TO THE BOARD OF DIRECTORS
PLATELET DISORDER SUPPORT ASSOCIATION

7555 Fredle Dr.
Suite 110

Concord, OH 44077

Phone: 440-951-2997

Fax: 866-359-4674

We have audited the accompanying financial statements of the Platelet Disorder Support Association (a nonprofit PDSA), which comprise the statement of financial position as of December 31, 2016, and the related statements of activities, functional expenses and cash flows for the year then ended, and the related notes to the financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Platelet Disorder Support Association as of December 31, 2016 and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Emphasis of Matter

The financial statements of the Platelet Disorder Support Association as of December 31, 2015 were audited by other auditors whose report dated July 24, 2016 expressed an unmodified opinion on those statements. These previously issued financial statements have been restated for the correction of a material misstatement as described in Note 7.

Report on Summarized Comparative Information

The prior-year summarized comparative information has been derived from Platelet Disorder Support Association's 2015 financial statements and, as described above, other auditors expressed an unmodified opinion on those financial statements.

Cleveland, Ohio
April 5, 2017

H&J
Certified Public Accountants



The CPA. Never Underestimate The Value.®

www.h-jcpa.com

PLATELET DISORDER SUPPORT ASSOCIATION

STATEMENTS OF FINANCIAL POSITION

DECEMBER 31, 2016 AND 2015

	UNRESTRICTED	TEMPORARILY RESTRICTED	2016	2015
ASSETS				
CURRENT ASSETS				
Cash & Cash Equivalents	\$ 367,389	\$ 236,748	\$ 604,137	\$ 532,292
Investments	247,162	-	247,162	246,715
Grant Receivable	-	10,000	10,000	20,100
Accounts Receivable	31,202	-	31,202	28,465
Prepaid Expenses	300	-	300	10,957
	<u>646,053</u>	<u>246,748</u>	<u>892,801</u>	<u>838,529</u>
FIXED ASSETS				
Furniture	28,371	-	28,371	28,371
Software	25,227	-	25,227	25,227
Computer Equipment	8,879	-	8,879	8,879
	<u>62,477</u>	<u>-</u>	<u>62,477</u>	<u>62,477</u>
Less Accumulated Depreciation	<u>(43,585)</u>	<u>-</u>	<u>(43,585)</u>	<u>(35,446)</u>
	<u>18,892</u>	<u>-</u>	<u>18,892</u>	<u>27,031</u>
OTHER ASSETS				
Investments	270,000	-	270,000	270,000
Deposits	21,742	-	21,742	16,742
	<u>291,742</u>	<u>-</u>	<u>291,742</u>	<u>286,742</u>
	<u>\$ 956,687</u>	<u>\$ 246,748</u>	<u>\$ 1,203,435</u>	<u>\$ 1,152,302</u>
LIABILITIES AND NET ASSETS				
CURRENT LIABILITIES				
Accounts Payable and Accrued Expenses	\$ 11,469	\$ -	\$ 11,469	\$ 10,033
Deferred Revenue	2,520	-	2,520	19,600
Accrued Compensation	44,630	-	44,630	28,841
	<u>58,619</u>	<u>-</u>	<u>58,619</u>	<u>58,474</u>
NET ASSETS				
Unrestricted - Board-Designated Research	34,036	-	34,036	18,253
- Board-Designated Contingency	270,000	-	270,000	270,000
- Operating	594,032	-	594,032	546,683
	<u>898,068</u>	<u>-</u>	<u>898,068</u>	<u>834,936</u>
Temporarily Restricted	-	246,748	246,748	258,892
Total Net Assets	<u>898,068</u>	<u>246,748</u>	<u>1,144,816</u>	<u>1,093,828</u>
Total Liabilities & Net Assets	<u>\$ 956,687</u>	<u>\$ 246,748</u>	<u>\$ 1,203,435</u>	<u>\$ 1,152,302</u>

See accompanying notes.

PLATELET DISORDER SUPPORT ASSOCIATION

STATEMENT OF ACTIVITIES

YEAR ENDED DECEMBER 31, 2016

	<u>UNRESTRICTED</u>	<u>TEMPORARILY RESTRICTED</u>	<u>TOTAL</u>
PUBLIC SUPPORT & REVENUE			
Foundation Grants	\$ 169,819	\$ 158,400	\$ 328,219
Conference	213,526	-	213,526
Contributions - Membership	120,235	-	120,235
Contributions - General	98,275	17,990	116,265
Corporate Sponsorship	53,520	-	53,520
Other Revenue	17,233	-	17,233
Merchandise Sales	10,976	-	10,976
Investment Income	4,018	-	4,018
Net Assets Released from Restrictions	<u>188,534</u>	<u>(188,534)</u>	<u>-</u>
TOTAL PUBLIC SUPPORT AND REVENUE	876,136	(12,144)	863,992
EXPENSES			
Programs	681,109	-	681,109
General and Administrative	83,096	-	83,096
Fundraising	<u>48,799</u>	<u>-</u>	<u>48,799</u>
TOTAL EXPENSES	<u>813,004</u>	<u>-</u>	<u>813,004</u>
CHANGE IN NET ASSETS	63,132	(12,144)	50,988
NET ASSETS - Beginning of Year	<u>834,936</u>	<u>258,892</u>	<u>1,093,828</u>
NET ASSETS - End of Year	<u><u>\$ 898,068</u></u>	<u><u>\$ 246,748</u></u>	<u><u>\$ 1,144,816</u></u>

See accompanying notes.

PLATELET DISORDER SUPPORT ASSOCIATION

STATEMENT OF ACTIVITIES

YEAR ENDED DECEMBER 31, 2015

	UNRESTRICTED	TEMPORARILY RESTRICTED	TOTAL
PUBLIC SUPPORT & REVENUE			
Foundation Grants	\$ 86,406	\$ 176,400	\$ 262,806
Contributions - General	138,649	28,858	167,507
Conference	155,671	-	155,671
Contributions - Membership	122,363	-	122,363
Corporate Sponsorship	104,230	-	104,230
Merchandise Sales	11,319	-	11,319
Investment Income	3,206	-	3,206
Other Revenue	2,735	-	2,735
Net Assets Released from Restrictions	<u>178,021</u>	<u>(178,021)</u>	<u>-</u>
TOTAL PUBLIC SUPPORT AND REVENUE	802,600	27,237	829,837
EXPENSES			
Programs	590,509	-	590,509
General and Administrative	95,198	-	95,198
Fundraising	<u>43,882</u>	<u>-</u>	<u>43,882</u>
TOTAL EXPENSES	<u>729,589</u>	<u>-</u>	<u>729,589</u>
CHANGE IN NET ASSETS	73,011	27,237	100,248
NET ASSETS - Beginning of Year	<u>761,925</u>	<u>231,655</u>	<u>993,580</u>
NET ASSETS - End of Year	<u>\$ 834,936</u>	<u>\$ 258,892</u>	<u>\$ 1,093,828</u>

See accompanying notes.

PLATELET DISORDER SUPPORT ASSOCIATION

STATEMENT OF FUNCTIONAL EXPENSES

YEAR ENDED DECEMBER 31, 2016

	PROGRAMS	GENERAL & ADMINISTRATIVE	FUNDRAISING	TOTAL
Compensation	\$ 406,360	\$ 61,183	\$ 24,748	\$ 492,291
Conference	117,838	-	-	117,838
Professional Fees	36,306	8,890	-	45,196
Travel	31,230	-	875	32,105
Printing	16,489	868	7,067	24,424
Office Rent	19,166	1,030	413	20,609
Software	8,149	-	2,716	10,865
Event Costs	-	4,437	4,436	8,873
Depreciation	8,139	-	-	8,139
Postage and Delivery	6,989	368	388	7,745
Bank and Finance Charges	744	146	6,290	7,180
Office Supplies and Maintenance	4,314	650	266	5,230
Cost of Merchandise Sold	5,007	-	-	5,007
Exhibit Expenses	4,967	-	-	4,967
Telephone	3,778	568	234	4,580
Equipment Rental	2,509	377	155	3,041
Internet and IT	2,398	360	149	2,907
State Registration Fees	925	925	925	2,775
Utilities	2,217	333	137	2,687
Insurance	1,188	1,388	-	2,576
Payroll Processing	-	1,573	-	1,573
Scholarship	1,200	-	-	1,200
Dues and Subscriptions	509	-	-	509
Miscellaneous	387	-	-	387
Advocacy	300	-	-	300
Total Expenses	<u>\$ 681,109</u>	<u>\$ 83,096</u>	<u>\$ 48,799</u>	<u>\$ 813,004</u>

See accompanying notes.

PLATELET DISORDER SUPPORT ASSOCIATION

STATEMENT OF FUNCTIONAL EXPENSES

YEAR ENDED DECEMBER 31, 2015

	PROGRAMS	GENERAL & ADMINISTRATIVE	FUNDRAISING	TOTAL
Compensation	\$ 344,372	\$ 64,570	\$ 21,523	\$ 430,465
Conference	94,766	-	-	94,766
Professional Fees	34,469	16,000	-	50,469
Printing	18,330	965	5,551	24,846
Occupancy	18,530	996	399	19,925
Office Rent	12,997	-	-	12,997
Postage and Delivery	8,151	429	3,340	11,920
Travel	10,982	-	215	11,197
Software	5,545	-	5,496	11,041
Office Supplies and Maintenance	8,382	1,572	524	10,478
Bank and Finance Charges	1,064	2,655	2,613	6,332
Telephone	4,802	900	301	6,003
Depreciation	5,660	-	-	5,660
Insurance	3,289	1,583	-	4,872
Loss on Disposal of Fixed Assets	1,401	1,400	1,400	4,201
Internet and IT	3,321	623	207	4,151
Exhibit Expenses	4,048	-	-	4,048
Equipment Rental	2,855	535	178	3,568
Utilities	3,106	167	67	3,340
State Registration Fees	1,018	1,018	1,018	3,054
Event Costs	1,050	-	1,050	2,100
Payroll Processing	-	1,785	-	1,785
Miscellaneous	1,155	-	-	1,155
Dues and Subscriptions	902	-	-	902
Training and Meetings	314	-	-	314
Total Expenses	<u>\$ 590,509</u>	<u>\$ 95,198</u>	<u>\$ 43,882</u>	<u>\$ 729,589</u>

See accompanying notes.

PLATELET DISORDER SUPPORT ASSOCIATION

STATEMENTS OF CASH FLOWS

YEARS ENDED DECEMBER 31, 2016 AND 2015

	2016	2015
CASH FLOWS FROM OPERATING ACTIVITIES:		
Change in Net Assets	\$ 50,988	\$ 100,248
Adjustments to Reconcile Change in Net Assets to Cash Provided by Operating Activities:		
Depreciation	8,139	5,660
Loss on Disposal of Fixed Assets	-	4,201
Changes in Operating Assets and Liabilities which Provided (Used) Cash:		
Receivables	7,363	(12,620)
Inventory	-	7,642
Prepaid Expenses	10,657	(9,649)
Deposits	(5,000)	-
Accounts Payable and Accrued Expenses	1,436	(11,631)
Deferred Revenue	(17,080)	11,600
Accrued Compensation	15,789	13,804
Total Adjustments	21,304	9,007
Cash Provided by Operating Activities	72,292	109,255
CASH FLOWS FROM INVESTING ACTIVITIES:		
Sale(Purchase) of Investments	(447)	483
Purchase of Fixed Assets	-	(27,455)
Cash Used by Investing Activities	(447)	(26,972)
NET CHANGE IN CASH AND CASH EQUIVALENTS	71,845	82,283
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR	532,292	450,009
CASH AND CASH EQUIVALENTS, END OF YEAR	\$ 604,137	\$ 532,292

See accompanying notes.

PLATELET DISORDER SUPPORT ASSOCIATION

NOTES TO THE FINANCIAL STATEMENTS

DECEMBER 31, 2016 AND 2015

NOTES:

1. NATURE OF OPERATIONS AND MISSION STATEMENT

Platelet Disorder Support Association (PDSA) is a non-profit organization incorporated in the State of New Jersey in 1998 and is located in Cleveland, Ohio. The primary purpose of PDSA is to disseminate timely and accurate information about Immune Thrombocytopenic Purpura (ITP) and other platelet disorders, to encourage and foster pertinent research, and to provide means for patients and their relatives to share experiences, support and improve their medical care.

PDSA's mission is to enhance the lives of people with immune thrombocytopenia (ITP) and other platelet disorders through education, advocacy, research and support.

PDSA's web site address is www.pdsa.org.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

BASIS OF ACCOUNTING

The financial statements of PDSA have been prepared on the accrual basis of accounting and accordingly reflect all significant receivables, payables, and other liabilities.

BASIS OF PRESENTATION

PDSA is required to report information regarding its financial position and activities according to three classes of net assets: unrestricted, temporarily restricted, and permanently restricted.

RECLASSIFICATIONS

Certain amounts for the year ended December 31, 2015 have been reclassified to reflect comparability with the December 31, 2016 presentation.

FAIR VALUE

PDSA records its financial instruments at fair value using a fair value hierarchy. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). For the organization, financial assets reported at fair value are based upon quoted prices for identical assets in an active market that the organization has the ability to access (Level 1).

The estimated fair value amounts for specific groups of financial instruments are presented within the notes applicable to such items. Cash and cash equivalents, accounts receivable, and accounts payable are stated at cost, which approximates fair value, due to their short term maturity.

CASH AND CASH EQUIVALENTS

Cash and cash equivalents consist primarily of demand deposits and money market accounts in federally insured and privately insured accounts. At December 31, 2016, PDSA's cash balances exceeded federally insured limits by approximately \$101,000. PDSA maintains its cash with high quality financial institutions which it believes limit these risks.

PDSA considers all highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents.

PLATELET DISORDER SUPPORT ASSOCIATION

NOTES TO THE FINANCIAL STATEMENTS

DECEMBER 31, 2016 AND 2015

NOTES (CONTINUED):

ACCOUNTS RECEIVABLE

Accounts receivable are stated at the amount management expects to collect from outstanding balances. Management provides for probable collectible amounts through a provision for bad debt expense based on its assessment of the current status of individual receivables. Balances that are still outstanding after management has used reasonable collection efforts are written off through a charge to the allowance for doubtful accounts. The allowance for doubtful accounts at December 31, 2016 and 2015 was \$-0-.

PROPERTY AND EQUIPMENT

Property and equipment are stated at cost or at their estimated fair value at date of donation. Depreciation is provided using the straight-line method over the estimated useful lives of the assets.

Additions and betterments of \$1,000 or more are capitalized, while maintenance and repairs that do not improve or extend the useful lives of the respective assets are expensed currently.

TEMPORARILY RESTRICTED CONTRIBUTIONS AND NET ASSETS

When a donor restriction expires, that is when a stipulated time restriction ends or purpose restriction is accomplished, temporarily restricted net assets are reclassified to unrestricted net assets and are reported in the Statement of Activities as assets released from restriction. Although restricted contributions typically are reported as support that increases restricted net assets, they may be reported as unrestricted support if the restrictions are met in the same reporting period, the policy is followed consistently, and it is disclosed.

USE OF ESTIMATES

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

CONCENTRATION

For the years ending December 31, 2016 and 2015, one donor accounted for 22% and 30% of PDSA's total revenue, respectively.

RECOGNITION OF CONTRIBUTION REVENUE

Contributions received are recorded as unrestricted, temporarily restricted and permanently restricted support depending on the existence and/or nature of any donor restrictions. Temporarily restricted net assets are reclassified to unrestricted net assets upon satisfaction of time or purpose restrictions. Permanently restricted net assets represent endowment funds which are subject to donor restrictions that the contributed principal be invested in perpetuity and only the income be utilized.

PLATELET DISORDER SUPPORT ASSOCIATION

NOTES TO THE FINANCIAL STATEMENTS

DECEMBER 31, 2016 AND 2015

NOTES (CONTINUED):

PDSA considers all contributions to be unrestricted unless specifically restricted by the donor.

Unconditional promises to give that are expected to be collected within one year are recorded at net realizable value. Unconditional promises to give that are expected to be collected in future years are recorded at the net present value of their estimated future cash flows. The discounts on those amounts are computed using the risk-free interest rates applicable for the years in which the promises are received. Amortization of the discounts is included in contribution revenue. Conditional promises to give are not included as support until the conditions are substantially met.

Contributions of cash or other assets restricted to the acquisition of long-lived assets are recorded as temporarily restricted contributions. If there are no donor restrictions on the long-lived asset's use, the donor restrictions are considered met once the long-lived assets are acquired and the temporarily restricted net assets are reclassified to the unrestricted net asset class.

DONATED SERVICES

Donated services that are recognized in the financial statements either (a) create or enhance non-financial asset or (b) be specialized skills, provided by entities or persons possessing those skills that would be purchased if not donated. PDSA receives donated services from volunteers who assist in programs, administration/governance and special projects. No amounts have been recognized for donated services described above since they did not meet the criteria for recognition.

ADVERTISING

Advertising costs are expensed when incurred. Advertising expense amounted to \$-0- in 2016 and 2015.

INCOME TAX STATUS

PDSA is incorporated as a not-for-profit that is exempt from federal income taxes under Internal Revenue Code Section 501(c)(3) and is not considered a private foundation under Section 509(a)(1). PDSA currently has no unrelated business income. Accordingly, no provision for income taxes has been recorded.

PDSA's policy is to record a liability for any tax position taken that is beneficial to the PDSA, including penalties and interest, when it is more likely than not the position taken will be overturned by a taxing authority upon examination. Management believes there are no such positions as of December 31, 2016 and, accordingly, no liability has been accrued.

FUNCTIONAL EXPENSES

PDSA's costs of providing its various services have been classified on a functional basis in the statement of functional expenses. Accordingly, certain costs have been allocated between program, administrative and fundraising functions. Expenses are charged directly to these functional areas where possible. Remaining expenses are allocated using the best available method.

SUBSEQUENT EVENTS

PDSA has evaluated its subsequent events for potential recognition and/or disclosure in the December 31, 2016 financial statements through April 5, 2017, the date that the financial statements were available to be issued.

PLATELET DISORDER SUPPORT ASSOCIATION

NOTES TO THE FINANCIAL STATEMENTS

DECEMBER 31, 2016 AND 2015

NOTES (CONTINUED):

3. TEMPORARILY RESTRICTED NET ASSETS

At December 31 net assets were temporarily restricted for the following purposes:

2016				
	BEGINNING NET ASSETS	CONTRIBUTIONS	NET ASSETS RELEASED FROM RESTRICTION	ENDING NET ASSETS
ITP Booklet	\$ 16,400	\$ 26,400	\$ (16,400)	\$ 26,400
ITP Hotline	28,800	30,000	(28,800)	30,000
Peer Communications	3,334	60,000	(58,334)	5,000
Research	127,858	17,990	-	145,848
Educational Materials Translation	-	12,000	-	12,000
Web, Video and Newsletter	82,500	30,000	(85,000)	27,500
	<u>\$ 258,892</u>	<u>\$ 176,390</u>	<u>\$ (188,534)</u>	<u>\$ 246,748</u>
2015				
	BEGINNING NET ASSETS	CONTRIBUTIONS	NET ASSETS RELEASED FROM RESTRICTION	ENDING NET ASSETS
ITP Booklet	\$ -	\$ 16,400	\$ -	\$ 16,400
ITP Hotline	-	30,000	(1,200)	28,800
Peer Communications	-	40,000	(36,666)	3,334
Research	99,155	28,703	-	127,858
Web, Video and Newsletter	132,500	90,000	(140,000)	82,500
	<u>\$ 231,655</u>	<u>\$ 205,103</u>	<u>\$ (177,866)</u>	<u>\$ 258,892</u>

4. BOARD-DESIGNATED NET ASSETS

At its discretion, the Board redirects operating net assets to the "Research Fund" to support initiatives that lead to better outcomes for those affected by ITP. In 2016 and 2015, the Board approved a contribution to the Fund in the amount of \$15,783 and \$18,253, respectively. PDSA's research fund will provide grants to fund research that furthers the understanding of the pathogenesis, diagnosis and management of primary ITP.

In January 2008, the Board approved a "Contingency Fund" to create asset balances to allow for shortfalls from economic fluctuations, single or multi-year project opportunities, or capital expenditures. All withdrawals from the account require Board approval. Interest, gains and earnings from investments accrue to operations. All investment fees/expenses and fund-related investment losses, to the extent of cumulative board-designations, are borne by operating assets. There were no contributions by the Board to the Contingency Fund in 2016 and 2015.

PLATELET DISORDER SUPPORT ASSOCIATION

NOTES TO THE FINANCIAL STATEMENTS

DECEMBER 31, 2016 AND 2015

NOTES (CONTINUED):

5. COMMITMENTS

PDSA operates at its office in Cleveland, Ohio. Lease terms call for monthly rent of \$1,675 through March 31, 2018. PDSA also leases certain office equipment through March 2020. Rent expense amounted to \$23,000 for 2016 and 2015. Minimum annual lease payments are as follows:

2017	\$	23,888
2018		8,359
2019		3,184
2020		1,229
2021		-
	\$	<u>36,660</u>

6. DESCRIPTION OF PROGRAM SERVICES

PDSA's major programs and services are as follows:

Patient Education

We provide on-line and printed information that enhances the knowledge of the disease, treatments, and wellness practices. We investigate and report the most recent research findings and treatment recommendations via our website, three print publications, monthly e-newsletter, social media channels, and 29 educational booklets printed in multiple languages.

Support Services

Our services promote patient-to-patient, patient-to-physician, and patient-to-medical provider communication. We encourage patient involvement in treatment and life-style decisions. PDSA has 43 local support groups including the US, Canada, and New Zealand, and 2 groups via video conference, an annual patient/caregiver meeting, ITP Poke-R-Club for children with ITP, college scholarship program for teens and young adults with ITP, and a patient hotline.

Public Education

Through contacts with the media and the publication of educational materials, we strive to increase the amount of information presented and available about ITP and other platelet disorders. Our annual national walk/run unites patients and communities and raises public awareness. PDSA received the designation for National ITP Awareness MonthSM in 2010. Each September, we celebrate with activities throughout the month, with the last Friday of September as Sport Purple for Platelets DaySM, and the last week of September as Global ITP Awareness WeekSM. In 2016, PDSA formed the ITP International Alliance and created the website globalitp.org, with 28 countries represented.

Platelet Disorder Research and Advocacy

We assist and encourage research in the treatment of ITP and other platelet disorders through surveys and collaboration with patients, industry, physicians, and researchers. We attend medical conferences and health care-related meetings and report any significant research and news that pertains to diagnosis and treatment of ITP to our members. The *PDSA Research Program* funds, assists and encourages promising research with the potential to further understand the pathogenesis and management of primary ITP, raise the quality of life for patients, lead to new therapies, and find a cure. In 2016, we established the *ITP Natural History Study Registry*, an international patient-consented registry of individuals with ITP designed to gather data on the natural progression of ITP, diagnosis and treatment, management of care, quality of life, and clinician reporting. PDSA staff participate in numerous advocacy meetings in Washington, D.C., including Rare Disease Day and organizing the NIH/ASH Hill Day on Capitol Hill.